通过免疫组织化学评估结肠制瘤素M表达及英夫利昔单抗治疗皮质类固醇难治性急性重症溃疡性结肠炎的疗效 - Suppr

Colonic oncostatin M expression evaluated by immunohistochemistry and infliximab therapy outcome in corticosteroid-refractory acute severe ulcerative colitis.

作者信息

O'Connell Jim, Doherty Jayne, Buckley Amy, Cormican David, Dunne Cara, Hartery Karen, Larkin John, MacCarthy Finbar, McCormick Paul, McKiernan Susan, Mehigan Brian, Muldoon Cian, Ryan Ciara, O'Sullivan Jacintha, Kevans David

机构信息

Department of Gastroenterology, St James's Hospital, Dublin, Ireland.

Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland.

出版信息

Intest Res. 2022 Jul;20(3):381-385. doi: 10.5217/ir.2021.00073. Epub 2022 Mar 11.

DOI:10.5217/ir.2021.00073

PMID:35263959

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9344240/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/901e/9344240/2dbb07bbf801/ir-2021-00073f1.jpg

相似文献

Colonic oncostatin M expression evaluated by immunohistochemistry and infliximab therapy outcome in corticosteroid-refractory acute severe ulcerative colitis.

Intest Res. 2022 Jul;20(3):381-385. doi: 10.5217/ir.2021.00073. Epub 2022 Mar 11.

Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: early and late outcome and predictors of colectomy.

J Crohns Colitis. 2014 Aug;8(8):852-8. doi: 10.1016/j.crohns.2014.01.006. Epub 2014 Jan 25.

Accelerated Clearance of Infliximab is Associated With Treatment Failure in Patients With Corticosteroid-Refractory Acute Ulcerative Colitis.

J Crohns Colitis. 2018 May 25;12(6):662-669. doi: 10.1093/ecco-jcc/jjy028.

Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis.

Clin Gastroenterol Hepatol. 2008 Oct;6(10):1112-6. doi: 10.1016/j.cgh.2008.04.035.

Anti-tumour necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: result of an open study on 13 patients.

Dig Liver Dis. 2002 Sep;34(9):626-30. doi: 10.1016/s1590-8658(02)80204-3.

Hypoalbuminemia and Bandemia Predict Failure of Infliximab Rescue Therapy in Acute Severe Ulcerative Colitis.

Dig Dis Sci. 2021 Jan;66(1):199-205. doi: 10.1007/s10620-020-06177-7. Epub 2020 Mar 13.

Colectomy rate in acute severe ulcerative colitis in the infliximab era.

Dig Liver Dis. 2008 Oct;40(10):821-6. doi: 10.1016/j.dld.2008.03.014. Epub 2008 May 9.

Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study.

Aliment Pharmacol Ther. 2012 Jan;35(2):275-83. doi: 10.1111/j.1365-2036.2011.04934.x. Epub 2011 Dec 5.

Infliximab induces clinical, endoscopic and histological responses in refractory ulcerative colitis.

Rev Esp Enferm Dig. 2004 Feb;96(2):94-101. doi: 10.4321/s1130-01082004000200002.

Infliximab as a rescue therapy for hospitalized patients with severe ulcerative colitis refractory to systemic corticosteroids.

Dig Surg. 2008;25(5):383-6. doi: 10.1159/000170882. Epub 2008 Nov 13.

引用本文的文献

Tryptanthrin Down-Regulates Oncostatin M by Targeting GM-CSF-Mediated PI3K-AKT-NF-κB Axis.

Nutrients. 2024 Nov 28;16(23):4109. doi: 10.3390/nu16234109.

Role of Oncostatin M in the prognosis of inflammatory bowel disease: A meta-analysis.

World J Gastrointest Surg. 2024 Jan 27;16(1):228-238. doi: 10.4240/wjgs.v16.i1.228.

本文引用的文献

Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease.

Inflamm Bowel Dis. 2021 Oct 18;27(10):1564-1575. doi: 10.1093/ibd/izab032.

CRP/Albumin Ratio: An Early Predictor of Steroid Responsiveness in Acute Severe Ulcerative Colitis.

J Clin Gastroenterol. 2018 Jul;52(6):e48-e52. doi: 10.1097/MCG.0000000000000884.

Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management.

J Crohns Colitis. 2017 Jul 1;11(7):769-784. doi: 10.1093/ecco-jcc/jjx009.

Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.

Nat Med. 2017 May;23(5):579-589. doi: 10.1038/nm.4307. Epub 2017 Apr 3.

Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial.

Lancet Gastroenterol Hepatol. 2016 Sep;1(1):15-24. doi: 10.1016/S2468-1253(16)30003-6.

Oncostatin M mediates STAT3-dependent intestinal epithelial restitution via increased cell proliferation, decreased apoptosis and upregulation of SERPIN family members.

PLoS One. 2014 Apr 7;9(4):e93498. doi: 10.1371/journal.pone.0093498. eCollection 2014.

Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.

Gastroenterology. 2014 Jan;146(1):85-95; quiz e14-5. doi: 10.1053/j.gastro.2013.05.048. Epub 2013 Jun 2.

Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression.

Clin Gastroenterol Hepatol. 2007 Jan;5(1):103-10. doi: 10.1016/j.cgh.2006.09.033. Epub 2006 Dec 4.

Infliximab for induction and maintenance therapy for ulcerative colitis.

N Engl J Med. 2005 Dec 8;353(23):2462-76. doi: 10.1056/NEJMoa050516.

Review article: medical treatment of severe ulcerative colitis.

Aliment Pharmacol Ther. 2002 Jul;16 Suppl 4:7-12. doi: 10.1046/j.1365-2036.16.s4.2.x.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Colonic oncostatin M expression evaluated by immunohistochemistry and infliximab therapy outcome in corticosteroid-refractory acute severe ulcerative colitis.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献